The Canadian startup, BioSymetrics, uses machine learning frameworks coupled with in vivo experimental research (i.e. clinical trials in humans) to discover new drugs and is now using its technology to combat COVID-19. The company’s predictive methods are able to analyze emerging patient data to assist healthcare workers to make efficient and effective decisions.
In addition, BioSymetrics is partnering with clinicians to leverage international collaboration in order to de-bias and combine data to determine if any of its early-stage drugs may be effective in combating COVID-19. The company also announced it “will pursue any collaboration to have a positive impact against COVID,” inviting brands looking for an AI partner in the global fight against COVID-19 to collaborate.
Image Credit: Shutterstock